Product Information
REPATHA 140 MG/ML SYRINGE is a brand product labeled by Amgen Inc., priced at $281.6973 per ML under NDC 72511050101. Its NADAC has been published 69 times since Mar 5, 2025.
Strength
140 mg/mL
Manufacturer
Amgen Inc.NDC
72511050101
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Last Updated
6/17/2026
Active Ingredients
EVOLOCUMABApproval Type
Biologic (BLA)
FDA Application
BLA125522On Market Since
11/24/2024
Pharmacological Classes
Price Statistics
The NADAC for REPATHA 140 MG/ML SYRINGE has been published 69 times since Mar 5, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $281.6973 per ML |
|---|---|
| All-time high | $281.9135 (Jun 10, 2026) |
| All-time low | $275.4546 (May 21, 2025) |
| 52-week high | $281.9135 |
| 52-week low | $275.5845 |
| Median price | $276.2991 |
| Average price | $277.7586 |
| Largest weekly change | +2.0% (Jan 14, 2026) |
| Weeks tracked | 69 |
| Tracking since | Mar 5, 2025 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of REPATHA 140 MG/ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for REPATHA 140 MG/ML SYRINGE, manufactured by Amgen Inc., is $281.6973 per ML (NDC 72511050101), effective Jun 24, 2026.
How has the price of REPATHA 140 MG/ML SYRINGE changed over time?
Over the history we have for it, the NADAC for REPATHA 140 MG/ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 69 weekly CMS publications since Mar 5, 2025.
What are the highest and lowest recorded NADAC prices for REPATHA 140 MG/ML SYRINGE?
Since Mar 5, 2025, the NADAC for REPATHA 140 MG/ML SYRINGE has ranged from a low of $275.4546 (May 21, 2025) to a high of $281.9135 (Jun 10, 2026), with a median of $276.2991 per ML.
Are there cheaper alternatives to REPATHA 140 MG/ML SYRINGE?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as REPATHA 140 MG/ML SYRINGE, but none are currently priced below it.
Who manufactures REPATHA 140 MG/ML SYRINGE?
REPATHA 140 MG/ML SYRINGE (NDC 72511050101) is labeled by Amgen Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification